RecruitingNot ApplicableNCT05793034
Predictive Factors for Survival in Aggressive Meningiomas
Analysis of Predictive Factors for Overall and Progression-free Survival After Neurosurgery for Atypical or Anaplastic Meningioma
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
250 participants
Start Date
Jan 7, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Patient operated for atypical (grade 2) meningioma; or
- Patient operated for anaplastic (grade 3) meningioma;
- Timeframe for surgery, 1999-2019
Exclusion Criteria1
- \) Patient lost at follow-up
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTBiological biomarker assessment
IHC, PCR, NGS, methylome
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05793034
Related Trials
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
NCT0563661819 locations
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
NCT052782084 locations
Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures
NCT074137961 location
Abemaciclib in Newly Diagnosed Meningioma Patients
NCT059404931 location
Plasma Extracellular Vesicles in Meningioma Patients
NCT061049301 location